SequelSEC

UNITED THERAPEUTICS Corp UTHR

Pharmaceutical Preparations · CIK 0001082554 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$3.15B
Fiscal year ended 2026-06-30
Operating income
$1.40B
Fiscal year ended 2026-06-30
Free cash flow
$1.09B
Fiscal year ended 2026-06-30

UNITED THERAPEUTICS Corp (UTHR) reported revenue of $3.15B and net income of $1.31B for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from UNITED THERAPEUTICS Corp’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

UNITED THERAPEUTICS Corp income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$3.15B
Cost of revenue$437.20M
Gross profit$2.72B
Operating income$1.40B
Net income$1.31B
Research & development$551.50M
Weighted-average diluted sharesUnavailable
Pretax income$1.57B
Income tax expense$262.10M
Diluted EPSUnavailable
Selling, general & administrative$764.00M
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

UNITED THERAPEUTICS Corp balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$1.80B
Total assets$7.22B
Current assets$3.48B
Total liabilities$819.80M
Current liabilities$607.80M
Total equity incl. NCI$6.40B
Temporary (mezzanine) equityUnavailable
Inventory$193.80M
Accounts receivable$310.30M
GoodwillUnavailable
Long-term debtUnavailable
Accounts payableUnavailable

Cash flow

UNITED THERAPEUTICS Corp cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow$1.69B
Capital expenditures$592.20M
Investing cash flow$744.50M
Financing cash flow-$2.22B
Net change in cash$210.10M
Stock-based compensation$155.40M
Common dividends paidUnavailable
Common share repurchases$2.50B
Depreciation & amortization$91.50M

Derived

UNITED THERAPEUTICS Corp derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow$1.09B
Gross margin86.1%
Operating margin44.4%
FCF margin34.6%
SBC / revenue4.9%
Current ratio5.73x
Revenue YoY growth2.5%
Net margin41.6%
R&D / revenue17.5%
CapEx / revenue18.8%
Long-term debt / equityUnavailable
Effective tax rate16.7%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open UTHR in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-05View SEC filing
10-Q · Filed 2026-05-06View SEC filing
10-K · Filed 2026-02-25View SEC filing
10-Q · Filed 2025-10-29View SEC filing
10-Q · Filed 2025-07-30View SEC filing
10-Q · Filed 2025-04-30View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.